Identification and validation of inflammatory response genes linking chronic kidney disease with coronary artery disease based on bioinformatics and machine learning.

Journal: Scientific reports
Published Date:

Abstract

Coronary artery disease (CAD) commonly occurs and elevates the risk of cardiovascular events and mortality in chronic kidney disease (CKD) patients. The underlying pathogenesis of CKD-related CAD is believed to be closely linked to inflammatory responses. Here, we explored inflammation-related markers for early diagnosis and management of CAD in CKD patients. Through comprehensive bioinformatics analysis and machine learning techniques, glutamate cysteine ligase modifier subunit (GCLM), nuclear protein 1 (NUPR1), and prostaglandin E receptor 1 (PTGER1) were selected as hub biomarkers. Furthermore, GCLM and NUPR1 were demonstrated significantly upregulated in the two validation cohorts of CKD patients with or without hemodialysis, while the change in PTGER1 was not prominent. Additionally, GCLM and NUPR1 were identified as promising indicators to predict CAD in CKD patients. Our study deciphered the higher predictive genes for CAD associated with CKD that is related to inflammation, which provides novel insights into the diagnosis and therapeutic options.

Authors

  • Binhong Yang
    Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Xinyue Yang
    Shenzhen Prevention and Treatment Center for Occupational Diseases, Shenzhen, Guangdong, China.
  • Haoqi Sun
    Neurology Department, Massachusetts General Hospital, Wang 720, Boston, MA, USA.
  • Meijuan Cheng
    Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Jingjing Jin
    Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-Related Pathogens and Immunity, Wenzhou Medical University, Wenzhou, China.
  • Yunhui Wu
    Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Qi An
    School of Information Technology, Faculty of Science, Engineering and Built Environment, Deakin University, Geelong, VIC 3216, Australia.
  • Kaixing Yan
    Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Shenglei Zhang
    Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Yaling Bai
    Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Jinsheng Xu
    College of Informatics, Huazhong Agricultural University, Wuhan, Hubei Province, China.